National Phd in Systems Medicine
Doctoral programme (PhD)
A.Y. 2026/2027
Study area
Medicine and Healthcare
PhD Coordinator
The national doctoral program in Systems Medicine involves the participation of seven universities (UNIMI as the administrative site, Humanitas University, UNIBA, UNICatt, UNINA, UNITN, UNITO) and eight research centers. It is based on three main characteristics: competitive selection, intensive tutoring, and advanced training. The organizational model includes the effective sharing of educational and research activities among the different institutions involved, as well as exchange and mobility of professors and doctoral students, and forms of co-supervision.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Tutte le classi di laurea magistrale - All classes master's degree
Dipartimento di Oncologia ed Emato-Oncologia- Via Santa Sofia 9/1 20122 Milano MI Italia
- Main offices
Dipartimento di Oncologia ed Emato-Oncologia - Via Santa Sofia 9/1 20122 Milano MI Italia - Degree course coordinator: Pasini Diego
Via Adamello, 16 - IFOM - Istituto FIRC di Oncologia Molecolare ed. 9
[email protected] - Degree course website
https://semm.it/training/scientific-courses/
| Title | Professor(s) |
|---|---|
| Identifying Functional Proteomic Signatures in Epithelioid Sarcoma |
A. Bachi (IFOM)
|
| Unveiling the dark proteome of cancer: Defining the Existence and Therapeutic Potential of Noncanonical ORFs in Cancer |
A. Bachi (IFOM)
|
| De novo discovery from RNA to Protein in patient-derived cancer models (AIRC-Calviello-MFAG 2025-32645-EI66A) |
L. Calviello (HT)
|
| A systems-level approach to unravel the crosstalk between tumor microenvironment and ovarian cancer stem cells |
U. Cavallaro (IEO)
|
| Crosstalk between tumor vasculature and ovarian cancer stem cells: the new role of L1CAM |
U. Cavallaro (IEO)
|
| Decoding the splicing code of KRAS G12C inhibitor resistance in lung adenocarcinoma | |
| RNA regulatory networks in translational oncology | |
| Synthetic Lethality Approaches to selectively kill BRCA1 and BRCA2 Deficient Tumors by targeting DNA replication gaps | |
| Mastering the Survival Secrets of Cancer: Unveiling and Targeting the Hidden Mechanisms Behind Cancer Therapy Resistance and Cellular Endurance | |
| How DNA Repair Proteins Integrate Multiple DNA Metabolism Pathways to Safeguard Genome Stability | |
| The ATM dependent signal transduction pathway and its links with cellular metabolism in normal cells and in Ataxia Telangiectasia | |
| How do tumor cells accumulate extrachromosomal circular DNA? |
Y. Doksani (IFOM)
|
| Investigating telomere loss during replication |
Y. Doksani (IFOM)
|
| Conditioning the gut ecosystem to enhance checkpoint inhibitors efficacy via enterotropic T cells (AIRC IG 2025 ID 32366) |
F. Grassi
|
| Monitoring immunesurveillance: Analysis of repetitive Elements and Fragmentomics in Tissue and Blood |
C. Tripodo
S. Marsoni (IFOM)
G. Crisafulli (IFOM)
|
| The Restrictor complex and the control of extragenic transcription (acronimo "RESET") - bando FIS 2 |
G. Natoli (IEO)
|
| Functional dissection of cerebral cavernous malformations epigenetic drivers using single-cell CRISPR screens |
M. Pagani
|
| Novel hypoxia-based regulatory T cell programs in tumor-immune communication |
M. Pagani
|
| Dissection of the regulatory networks that shape human T cells functional plasticity in the context of tumor immune responses |
M. Pagani
|
| Characterization of the molecular blueprints of T cell subsets at tumor site |
M. Pagani
|
| Genomic rearrangements at epithelial-gene enhancers as drivers of mesenchymal transition and metastatization in breast cancer: mechanisms of occurrence and transcriptional de-regulation (acronimo "REMOT") - bando FIS 3 | |
| Digital approaches to psychological screening in oncology |
G. Pravettoni
|
| Breast reconstruction. Preferences and needs of patients and satisfaction of long-term choices |
G. Pravettoni
|
| Psychological Wellbeing and Artificial Intelligence across cancer trajectory |
G. Pravettoni
|
| Impact of the intervention system and adherence to long-term care of the patient |
G. Pravettoni
|
| Metabolic Vulnerabilities and Adaptations in Aneuploid Cancers |
S. Santaguida
|
| Deciphering and exploiting aneuploidy in cancer |
S. Santaguida
|
| Molecular underpinnings of robustness in the epigenetic regulatory network (acronimo "EpiRobust") - bando FIS 3 |
P. Scaffidi (IEO)
|
| Modelling immunotherapy response in cancer |
M. Schaefer (IEO)
|
| The cancer code: unraveling selection across the cancer genome and epigenome |
M. Schaefer (IEO)
|
| Translational spatial profiling |
D. Schapiro (IFOM)
|
| Tumor Spatial Biology |
D. Schapiro (IFOM)
|
| Development and application of spatially resolved (single-cell) technologies to understand how tumors evolve, evade immune control, and respond to therapy |
D. Schapiro (IFOM)
|
| Building of computational and experimental tools to enable unprecedented insights into tissues in health and disease |
D. Schapiro (IFOM)
|
| Pathways, Risk Factors, And Molecules to Prevent Early-Onset Colorectal Tumors (CRUK PROSPECT) |
N. Segata (UNITN)
|
| Dissecting B cell fate decisions: integrating omics and imaging to reveal drivers of plasma cell differentiation |
B. Soskic (HT)
|
| Genetic and regulatory determinants of altered B cell function in immune diseases |
B. Soskic (HT)
|
| Investigating molecular and cellular determinants of B cell differentiation |
B. Soskic (HT)
|
| Elucidating the genetic control of T cell – B cell interaction and antibody production |
B. Soskic (HT)
|
| RNAseq-Driven Machine Learning framework for Predicting Immunotherapy Response (acronimo "PRIME") - bando FIS 3 | |
| Genome editing in liver for therapy of inherited diseases |
A. Auricchio (UNINA)
|
| New therapies for inherited metabolic disorders |
N. Brunetti (UNINA)
|
| Population genomics for surveillance of common and rare genetic diseases |
D. Cacchiarelli (UNINA)
|
| Dissecting and piloting the intracellullar tarfficking of AAVs |
A. De Matteis (UNINA)
|
| Engineering Synthetic Gene Circuits for advancing gene and cell therapy |
D. Di Bernardo (UNINA)
|
| Lysosomal signaling in metabolic diseases |
G. Napolitano (UNINA)
|
| The RNA world in Inherited Retinal Disease |
S.Banfi (UNINA)
|
Enrolment
Call for applications
Please refer to the call for admission test dates and contents, and how to register.
Application for admission: please refer to the call
Attachments and documents
Corrected announcement for XLII cycle of the Systems Medicine programme
Following the programme of study
Contacts
Office and services for PhD students and companies